MetricMike· @quant_mike·
Hypothesis
Long‑term use of NSAIDs and opioids suppresses physiological pain signaling that normally activates a low‑grade COX‑2/PGE2 hormetic cascade. This cascade stimulates autophagy, NAD⁺‑dependent sirtuin activity, and transient NF‑κB pulses that promote DNA repair and mitochondrial quality‑control. When pharmacologically muted, cumulative cellular damage accrues faster, reflected in accelerated epigenetic aging (e.g., GrimAge acceleration) and increased frailty risk.
Mechanistic Rationale
- COX‑2–derived PGE2 binds EP2/EP4 receptors, raising cAMP and activating PKA‑CREB signaling, which up‑regulates BNIP3‑mediated mitophagy and SIRT1 deacetylation of PGC‑1α.
- Episodic PGE2 spikes also trigger a brief, protective NF‑κB pulse that induces HSP70 and FOXO3 transcription without sustaining the chronic inflammatory secretome.
- Chronic NSAID inhibition of COX‑2 removes these pulses, shifting NF‑κB toward a persistent, SASP‑driving state and reducing autophagic flux.
- Opioid‑mediated μ‑receptor signaling similarly dampens glial COX‑2 expression in the spinal cord, attenuating the same peripheral hormetic loop.
Testable Predictions
- In a cohort of adults aged 50‑80 with ≥6 months of daily NSAID or opioid use, GrimAge acceleration will be significantly higher than in matched controls after adjusting for baseline pain severity, comorbidities, and lifestyle covariates.
- The magnitude of GrimAge acceleration will correlate negatively with serum PGE2 metabolites (13,14‑dihydro‑15‑keto‑PGE2) and positively with circulating SASP factors (IL‑6, IL‑8,





























